



**sirona**  
biochem

**Biotech  
Stock 2022**

TSX-V: SBM  
FSE: ZSB | OTC: SRBCF

June 27, 2022

# **Sirona Biochem** [TSX-V: SBM] is a **Strong Buy** and a potential **10-bagger**.

PRC Partners believes that Sirona Biochem is  
the **No. 1 biotech stock** to buy for 2022.

\*Warning: Conflict of Interest. PRC Partners is a shareholder. We are not financial advisors. Read our full disclaimer.

# About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery firm with a proprietary platform technology. Through its wholly-owned French subsidiary TFChem, the Company specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. Sirona Biochem’s business model is to develop active ingredients that are then licensed out for up-front payments, milestones and royalties.

FUNDAMENTAL DATA	(CAD)
TSX-V	SBM
Shares Outstanding	250,251,526
Shares Fully Diluted	275,187,486
Share Price (CAD)	\$0.27
Market Cap	\$67,567,912
Year High	\$0.35
Year Low	\$0.14

\*June 24, 2022

TSX VENTURE EXCHANGE **SBM**  
**CAD\$0.27**

OTCQB EXCHANGE **SRBCF**  
**USD\$0.22**

FRANKFURT STOCK EXCHANGE **ZSB**  
**EUR€0.20**


10 - B A G G E R P O T E N T I A L



# Proprietary Technology

- Sirona Biochem's **Fluorination Chemistry Technology** is the solution to unstable carbohydrate molecules.
- **Geraldine Deliencourt-Godefroy, PhD**, an award-winning synthetic chemist is leading the R&D team in France.
- The chemistry **strengthens the bonds** of carbohydrate molecules by strategically placing fluorine atoms.
- Sirona Biochem's Technology has received more than **\$8M CAD** from the French Government
- Strong patent portfolio, **TFC-1067 licensed to AbbVie**
- **Unlimited applications** for unique synthesized compounds as active ingredients.

Carbohydrate molecules are unstable by nature



Sirona's technology stabilizes carbohydrate molecule

# PRODUCT PIPELINE

## Cosmetic Products



**sirona**  
biochem

**TFC-1067**  
An Innovative  
Dark Spot Corrector  
MAY 2022

TSX-V: SBM  
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH.

**Game Changer**



**sirona**  
biochem

**TFC-1326**  
Anti-Aging  
Anti-Wrinkle

TSX-V: SBM  
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH.

**Anti-Aging Revolution**



**sirona**  
biochem

**TBA**  
Cellulite Treatment

TSX-V: SBM  
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH.

## Pharmaceutical Products



**sirona**  
biochem

**TFC-039**  
Animal Health

TSX-V: SBM  
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH.

**Projected Deal 2022**



**sirona**  
biochem

**Anti-Viral**

TSX-V: SBM  
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH.

## TRIPLE WHAMMY

**Sirona Biochem** has a strong product pipeline. We want to focus on **TFC-1067, TFC-039 and TFC-1326** as these compounds have the most potential in generating substantial revenue, which will impact the stock considerably in the short term.

# TFC-1067 - AbbVie Deal

- ▶ Sirona Biochem signed a [global exclusive licensing deal](#) with **AbbVie's Allergan Aesthetics** for TFC-1067, touted as the new “Gold Standard” in the \$8B USD skin-lightening market.
- ▶ The Botox maker, which generated \$56B USD (2021) in revenue last year, plans to **market and commercialize TFC-1067**. This is a match made in heaven, given AbbVie's significant market reach in the cosmetics industry.
- ▶ We estimate that AbbVie will take around 10% of the \$8B USD skin-lightening market, which equates to an estimated **\$40M USD** in annual royalty payments for Sirona Biochem. **\$680M USD** in total over 17 years.
- ▶ AbbVie withheld figures involving its upfront and milestone payments to Sirona Biochem as they likely did not want their competitors to see the amount of resources they are committing to this project.

TSX-V: SBM  
FSE: ZSB | OTC: SRBCF

# TFC-039 - Animal Health

- ▶ Management sees a realistic chance of a deal being made for TFC-039 by the **end of 2022**.
- ▶ Sirona Biochem would be one of the first companies in the market to offer a non-invasive treatment for pet diabetes.
- ▶ Already established a full production agreement with **Wanbang Biopharma** for TFC-039.
- ▶ Currently in talks with **four animal pharmaceutical companies** for TFC-039.

## Top 5 Animal Pharmaceutical Companies and Revenue

Merck

**\$47.99B USD**

Boehringer Ingelheim

**\$22B USD**

Zoetis

**\$7.78B USD**

Covertus

**\$4.33B USD**

Elanco

**\$3.27B USD**

TSX-

FSE: ZSB | OTC: SRBCF

# TFC-1326 - Anti-Aging

- ▶ TFC-1326 is a patented glycopeptide treatment that **reverses age-related damage** to the skin.
- ▶ Expected to complement or replace existing skin anti-aging treatments and products.
- ▶ Sirona Biochem signed a limited-batch manufacturing deal with Wuxi AppTec to **begin human clinical trials.**
- ▶ The anti-aging market is forecasted to reach **\$271B USD**, with anti-wrinkle products accounting for 59.3% of the total.
- ▶ Tapping even a portion of this multi-billion market would translate to **inconceivable royalty-payment** revenue for Sirona Biochem.

TFC-1326  
Anti-Aging  
Anti-Wrinkle

TSX-V: SBM  
FSE: ZSB | OTC: SRBCF

# Go In-depth

PRC Partners recommends that you do your own research. We encourage you to visit the company's website at [www.sironabiochem.com](http://www.sironabiochem.com) or check out the resources we have provided below.



Sirona Biochem's investor's presentation gives a clear overview of the company, its operations, technology and other information relevant to prospective investors.

DOWNLOAD



We sat down with Sirona Biochem's top management to find out more about what's next for the company following its deal with AbbVie.

DOWNLOAD



Read our interview with Sirona Biochem's new Advisory Board member, former Bayer executive Dr. Wolfgang Bieber.

DOWNLOAD

# Conclusion

---

## Institutional Investors

We have had long conversations with the company's management over the past few days, and they have expressed excitement over the company's future. Since the AbbVie deal was announced, Sirona Biochem has been approached by several major institutions, funds and investment banking firms. Initial meetings have already taken place and will be followed up by high-profile meetings all over the world in the coming weeks. As far as we know, additional meetings will take place in Germany, France, the U.S and Canada.

We acknowledge that the initial impact of the AbbVie deal was not as expected, given the unfavorable market conditions, the nondisclosure of the amount of the upfront payment and the lag of institutional support. However, we believe that is about to change given the continually rising institutional interest, which should ignite the stock. As of now, Sirona Biochem remains undervalued, but this should change once the institutions come on board, and we anticipate this to happen very soon.

# Conclusion

---

## Management Changes And Additions

Following the AbbVie deal, there has been a lot of movement within the company, including the signing of new deals and the accelerated development of several products in its pipeline. As mentioned in its previous corporate update, Sirona Biochem has now brought in experienced talent to enact substantial changes, including a planned management structure overhaul. Management changes will take place in France, as well as in North America, under the guidance of the company's new Advisory Board member, former BAYER AG executive Dr. Wolfgang Bieber.

In a recent conversation with the current CEO, Dr. Howard Verrico, we were made aware that the company has already begun the process of looking for a suitable CEO, either one from Europe or a multi-lingual candidate, to take the company to the next level. Dr. Verrico would remain with the company as president and chairman of the board. Further, there will be additions to the current management structure to handle the increasing workload and to enable the science team, led by Dr. Geraldine Deliencourt-Godefroy, to focus on non-scientific tasks.

# Conclusion

---

## Triple Whammy

The additional resources gained from the AbbVie deal should enable the company to increase its investments in its workforce, facility and pipeline, which may translate to additional milestone deals and breakthrough products. This will, in turn, bring in more money to start the cycle again. PRC Partners believes in the immeasurable potential in the company's current pipeline, particularly the company's anti-aging compound TFC-1326, its anti-diabetes treatment TFC-039 and its recently licensed skin-lightening ingredient TFC-1067.

Whichever company licenses TFC-1326 could potentially become a major player in the \$271B USD anti-aging market. The potential here is inconceivable. Based on pre-clinical data and on statements made by management, TFC-1326 has the potential to replace or supplement dermal filler injections to treat age-related skin damage and wrinkles. Sirona Biochem is currently in the process of conducting human clinical trials for TFC-1326, a product that we believe would have the most impact on the company's growth.

AbbVie is already in the advanced stages of its development and commercialization process for TFC-1067. While we agree with the assessment that it might still take a few months for the company to be ready to release a commercial product based on the compound, we can't stress enough the potential impact of that product and the revenue it would generate for Sirona Biochem through royalty payments.

# Conclusion

---

Dr. Verrico reaffirmed in our recent conversation his commitment to closing a licensing deal for TFC-039 by the end of 2022. The animal health market may not be as large as the anti-aging market, but a deal with a top animal pharmaceutical company could still translate to tens of millions of dollars in royalty payments.

## **STRONG BUY Rating**

We still stand firm in our belief that Sirona Biochem is a diamond in the rough, a sparkling gem that requires a bit of polishing but one that can potentially outshine all of the biotech stocks on the small-cap market. If things pan out as expected, the company could become a major provider of patented active ingredients in the aesthetics, cosmetics, and pharmaceutical sector. Further, once they get institutional commitment, Sirona Biochem will be playing at a completely different level. Shareholders, particularly those that have stuck with the company, will finally have their day in the sun.

# Investment Highlights

- **Signed** global exclusive **licensing deal** with **Allergan Aesthetics**, an **AbbVie** [NYSE: ABBV] company, for **TFC-1067** and library of cosmetic compounds.
- **Ongoing royalty payments** for compound discoveries, including **upcoming royalties** on net sales generated by **AbbVie** product line based on licensed patented ingredients. Cooperating on additional products with AbbVie. **17 years** duration for TFC-1067 patents.
- **Disruptive** proprietary carbohydrate-bonding platform based on 20 years of research and development.
- Strong worldwide IP portfolio, including North America, European Union, and Asia.
- **Cosmetics** - Developing disruptive solutions for anti-aging (\$271B USD), cell preservation (\$7.5B USD), and cellulite treatment (\$1.4B USD).
- **Pharmaceutical** - TFC-039, first-in-market ingestible tablet to treat animal diabetes. In advanced partnership talks with four major animal health companies.
  - Developing Anti-viral TBD compound for \$36B USD anti-viral market.
- State-of-the-art, multi-million dollar laboratory in France with top scientific team, strong| **global manufacturing partners** for pharmaceutical (**Wanbang Pharma**, China) and cosmetics (**Wuxi AppTec**, China).
- Sirona Biochem signed a **limited-batch manufacturing deal** for TFC-1326 with Wuxi AppTec in order to begin human clinical trials.
- In talks with several institutional investors, brokerages and investment funds in Europe and North America

# Disclaimer

---

The information contained on this website and the resources available for download through this website is not intended as, and shall not be understood as, financial advice. We are not attorneys, accountants or financial advisors, nor are we holding ourselves out to be, and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation.

We have done our best to ensure that the information provided on this Website and the resources available for download are accurate and provide valuable information. Regardless of anything to the contrary, nothing available on or through this Website should be understood as a recommendation that you should not consult with a financial professional to address your particular information. PRC Partners expressly recommends that you seek advice from a professional.

Conflict of Interest. PRC Partners is a shareholder in Sirona Biochem and reserves the right to buy or sell, have long or short positions in this stock at any time, without giving any notice. PRC Partners is being payed by Sirona Biochem for consulting services to further its business development across the globe.

Stock speculation is very risky, Do not trade with more than you can afford to lose, seek professional investment advice, this is not investment advice, No warranties, you are on your own.